Efficacy of an Attention Guidance VR Intervention for Social Anxiety Disorder

December 28, 2021 updated by: Michael J. Telch, University of Texas at Austin
Social anxiety disorder (SAD) is a prevalent mental health concern that impacts approximately 12% of the population. One mechanism thought to maintain SAD is avoidance of faces (i.e. avoidance of negative evaluative threat). However, research on attentional processes in SAD has been confined to paradigms presented on computer monitors. To investigate attentional processes in a more naturalistic way the investigators developed an immersive, 360º-video virtual reality environment using real actors, as part of a pilot study. Participants with a range of social anxiety symptoms (from none to severe) completed a 5-minute speech in this virtual reality environment while their eye movements were recorded. Results from the study showed that greater symptoms of social anxiety were associated with avoidance of looking at faces (i.e. fewer fixations on faces). While existing treatments for SAD are moderately effective, a large number of individuals do not experience meaningful reductions in their symptoms. The overarching goal of this project is inform future treatment research for SAD. The investigators will test a brief attention guidance intervention for SAD that specifically targets avoidance of faces as a potential mechanism maintaining the disorder. The proposed research will use the eye tracking hardware and naturalistic virtual reality environment from the pilot study. The investigators will also collect eye tracking data prior to the intervention in order to investigate potential heterogeneity in the attentional processes of SAD. The investigators will test the hypotheses that (a) the attention guidance intervention, compared to the control intervention, will result in a greater reduction in symptoms of social anxiety, and (b) this effect will be mediated by the number of fixations on faces during a brief public speaking challenge following the intervention. These results will provide causal evidence related to a hypothesized mechanism maintaining SAD.

Study Overview

Study Type

Interventional

Enrollment (Actual)

21

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Texas
      • Austin, Texas, United States, 78712
        • The University of Texas at Austin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age 18-65;
  2. Fluent in English;
  3. Personal Report of Public Speaking Anxiety score > 98;
  4. Leibowitz Social Anxiety Scale > 30;
  5. Peak fear ≥ 50 on the behavioral approach task during the baseline assessment;
  6. Meets DSM-5 Criteria for Social Anxiety Disorder.

Exclusion Criteria:

  1. Currently receiving CBT for Social Anxiety Disorder;
  2. Significant visual impairment precluding the use of virtual reality equipment;
  3. Unstable dose of psychotropic medications within 3 weeks prior to baseline assessment;
  4. Current alcohol or substance use disorders;
  5. Current, or history of bipolar disorder; current, or history of psychosis;
  6. Serious suicidal risk, as determined by clinical interview.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Attention guidance
In addition to the components included in the control intervention the experimental attention guidance condition consists of three unique components: (1) the rationale will include information about the importance of visually attending to the faces of the audience; (2) in addition to being given a speech topic, participants will be given target audience members to focus their gaze on during the speech. They will be told that they should look at and focus on the target audience member for the whole speech; (3) between speeches, the researcher will tell participants the percentage of time they were focused on the target face.
Explicitly guiding attention towards faces during public speaking exposures
Active Comparator: Control intervention

Participants will complete two intervention sessions within one week. The intervention will use a manualized protocol.

  1. On the first session, participants will receive a brief standardized psychoeducation module, presented via a 15-minute video recording. This video will explain the intervention, its rationale, and the procedure.
  2. Participants will then have 5 minutes to plan and outline a speech based on a topic given to them. All participants will receive the same topic. Participants will not be allowed to use the outline during the public speaking exposure trials.
  3. Participants will then give six speeches that are each 3 minutes long on the same topic. Participants will give all the speeches in the immersive 360º-video environment.
  4. Between speeches participants will have a 1-minute break.
Public speaking exposures

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Personal Report of Public Speaking Anxiety Scale Post-intervention
Time Frame: Immediately following the end of the 1-week intervention
Questionnaire that assesses fear of public speaking Score range (total summed score): 34-170; Higher score reflects greater public speaking anxiety
Immediately following the end of the 1-week intervention
Personal Report of Public Speaking Anxiety Scale at 1-week
Time Frame: 1-week follow-up
Questionnaire that assesses fear of public speaking Score range: 34-170 (total summed score); Higher score reflects greater public speaking anxiety
1-week follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Leibowitz Social Anxiety Scale Post-intervention
Time Frame: Immediately following the end of the 1-week intervention
Questionnaire that assesses generalized social anxiety Score range (total summed score): 0-144; Higher scores reflect greater social anxiety
Immediately following the end of the 1-week intervention
Leibowitz Social Anxiety Scale at 1-week
Time Frame: 1-week follow-up
Questionnaire that assesses generalized social anxiety Score range (total summed score): 0-144; Higher scores reflect greater social anxiety
1-week follow-up
Speech Anxiety Thoughts Inventory Post-intervention
Time Frame: Immediately following the end of the 1-week intervention
Assesses cognitions associated with social anxiety Score range (total summed score): 23-115; Higher scores reflect greater severity
Immediately following the end of the 1-week intervention
Speech Anxiety Thoughts Inventory at 1-week
Time Frame: 1-week follow-up
Assesses cognitions associated with social anxiety Score range (total summed score): 23-115; Higher scores reflect greater severity
1-week follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2019

Primary Completion (Actual)

March 11, 2020

Study Completion (Actual)

March 25, 2020

Study Registration Dates

First Submitted

July 20, 2018

First Submitted That Met QC Criteria

September 22, 2018

First Posted (Actual)

September 25, 2018

Study Record Updates

Last Update Posted (Actual)

March 11, 2022

Last Update Submitted That Met QC Criteria

December 28, 2021

Last Verified

December 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • 2018-04-0011

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Social Anxiety Disorder

Clinical Trials on Attention guidance

3
Subscribe